Atenstad 50

Atenstad 50 contains atenolol, a hydrophilic beta-adrenergic receptor blocking agent with relative β1 selectivity (‘cardioselectivity’) without intrinsic sympathomimetic and membrane stabilising activities. As a function to reduce of sympathetic tone, atenolol reduces heart rate, cardiac contractility, AV conduction velocity and plasma renin activity.

Pack size Box of 100 tablets
Shelf-life 24 months
Composition Atenolol
Dosage forms and strengths Film-coated tablet: 50 mg
Product code :



Treatment of hypertension, angina pectoris, cardiac dysrhythmia, and for early intervention in the acute phase of myocardial infarction.


  • Hypertension: The use initial adult oral dosage is 25 – 50 mg once daily. The full hypotensive effect may be seen after 1 to 2 weeks. Oral dosage may be increased to 100 mg once daily for optimum response.
  • Chronic stable angina pectoris: The initial adult oral dosage is 50 mg once daily. If an optimum response is not achieved within one week, oral dosage should be increased to 100 mg once daily.
  • Cardiac arrhythmias: Following control with intravenous atenolol, a suitable oral maintenance dosage is 50 – 100 mg daily, given as a single dose.
  • Early management of acute myocardial infarction:
    Patients tolerating the total IV dose of 10 mg can receive 50 mg orally 10 minutes later and then 50 mg orally 12 hours later. Dosing is continued orally for 6 – 9 days at 100 mg daily given as a single daily dose or in 2 equally divided doses.
  • Patients with renal insufficiency:
    The dose of atenolol should be reduced in patients with renal impairment, depending on the creatinine clearance (CC) as follows:
    CC 15 – 35 ml/minute per 1.73 m2: A maximum dosage of 50 mg daily is recommended.
    CC less than 15 ml/minute per 1.73 m2: 25 mg daily or 50 mg every other day.
    Dialysis patients: 25 – 50 mg orally after each dialysis.


Atenstad 50 is administered orally before meals.

  • Patients with sinus bradycardia, AV block greater than first degree, cardiogenic shock, known hypersensitivity to any component of the drug formulations, and overt or decompensated cardiac failure.
  • Concomitant therapy with verapamil.
  • Fatigue, dizziness, drowsiness, mild headache, sweating, and cold extremities.
  • Exacerbation of peripheral occlusive disease, reduced lacrimation, conjunctivitis, hypoglycemia in diabetic patients, muscle cramps/ weakness and impotence have also been reported.
  • The dosage should be gradually reduced within 2 weeks before stopping the treatment with atenolol.
  • Particularly careful medical monitoring is necessary in:
    – Patients with asthma or a history of obstructive airways disease.
    – Diabetics with highly unstable blood glucose concentrations.
    Patients following an absolute diet for prolonged periods of time and those subject to great physical exertion.
    Patients with pheochromocytoma (tumour of the adrenal medulla; prior alpha-blocker therapy is indicated).
    Patients with impaired kidney function.
  • Only use if clearly needed in patients with a history of severe hypersensitivity reactions and those receiving specific hyposensitisation therapies (because of the risk of exaggerated anaphylactic reactions); patients with a history or family history of psoriasis.
  • The application of atenolol could cause positive results in doping tests.
  • Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose – galactose malabsorption should not take atenolol.
  • Atenolol should be used during pregnancy only if clearly needed and after a careful benefit/risk assessment. Particularly careful monitoring is indicated when using atenolol during lactation.
  • Patients should be aware of how they react to drug before driving or operating machinery.